Docoh
Loading...

TVTX Travere Therapeutics

News

Pro users get this 30m faster
8 Health Care Stocks With Unusual Options Alerts In Today's Session
16 Sep 21
Options
This unusual options alert can help traders track potentially big trading opportunities. Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Unusual trading activity could push option prices to hyperbolic or underperforming levels. Here's the list of some unusual options activity happening in today's session:
The Daily Biotech Pulse: Leap, Phio, Silverback Among Early Movers On Oncology Conference Presentations, Aerie Slumps On Mixed Data, Axsome Commences Phase 3 Sleep Disorder Study
16 Sep 21
Biotech, News, Penny Stocks, Offerings, Small Cap, FDA, General
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 15)
12 Health Care Stocks Moving In Wednesday's After-Market Session
15 Sep 21
Movers
Gainers
Travere Therapeutics And Vifor Pharma Announce Licensing Agreement For The Commercialization Of Sparsentan In Europe, Australia And New Zealand
15 Sep 21
News, Contracts
Vifor Pharma obtains exclusive commercialization rights for sparsentan in Europe, Australia and New Zealand Travere receives a $55 million upfront payment and is eligible for additional regulatory and
See Why Travere Therapeutics Stock Moving Higher On Tuesday
7 Sep 21
Biotech, News, Health Care, Small Cap, FDA, Movers, Trading Ideas, General
Travere Therapeutics Sam.gov Contract For ~$15M Contract Via Dept. Of Veterans Affairs Federal Supply Schedule
19 Aug 21
News, Contracts
https://sam.gov/opp/eac3629bbc3a45ba9533cbfdd5fdecf1/view
60 Biggest Movers From Yesterday
17 Aug 21
News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas
Gainers NanoVibronix, Inc. (NASDAQ: NAOV) shares jumped 33.7% to close at $3.37 on Monday after the company announced plan to expand product portfolio with introduction of Painshield relief for over-the-counter use and plans for future product launch.
SVB Leerink Maintains Outperform on Travere Therapeutics, Raises Price Target to $37
17 Aug 21
News, Price Target, Analyst Ratings
SVB Leerink analyst Joseph Schwartz maintains Travere Therapeutics (NASDAQ:TVTX) with a Outperform and raises the price target from $27 to $37.
Mid-Afternoon Market Update: Dow Turns Positive; Sesen Bio Shares Plummet
16 Aug 21
Earnings, News, Penny Stocks, Eurozone, Commodities, Small Cap, Global, Intraday Update, Markets
Toward the end of trading Monday, the Dow traded up 0.03% to 35,526.99 while the NASDAQ fell 0.34% to 14,771.91. The S&P also rose, gaining 0.02% to 4,468.88.
12 Health Care Stocks Moving In Monday's Intraday Session
16 Aug 21
Intraday Update, Markets, Movers
Mid-Day Market Update: Crude Oil Down Over 2%; Travere Therapeutics Shares Jump
16 Aug 21
Earnings, News, Penny Stocks, Eurozone, Commodities, Small Cap, Global, Intraday Update, Markets
Midway through trading Monday, the Dow traded down 0.36% to 35,388.46 while the NASDAQ fell 1.24% to 14,639.36. The S&P also fell, dropping 0.54% to 4,443.76.
38 Stocks Moving In Monday's Mid-Day Session
16 Aug 21
News, Penny Stocks, Small Cap, Intraday Update, Markets, Movers, Trading Ideas
Gainers NanoVibronix, Inc. (NASDAQ: NAOV) shares climbed 34.5% to $3.3900 after the company announced plan to expand product portfolio with introduction of Painshield relief for over-the-counter use and plans for future product launch.
Mid-Morning Market Update: Markets Open Lower; Empire State Manufacturing Index Dips In August
16 Aug 21
Earnings, News, Penny Stocks, Eurozone, Commodities, Small Cap, Global, Intraday Update, Markets
Following the market opening Monday, the Dow traded down 0.40% to 35,372.03 while the NASDAQ fell 1.27% to 14,634.24. The S&P also fell, dropping 0.57% to 4,442.47.
12 Health Care Stocks Moving In Monday's Pre-Market Session
16 Aug 21
Pre-Market Outlook, Markets, Movers
Travere Therapeutics Stock Is Trading Higher On Positive Data From Kidney Disease Candidate
16 Aug 21
Biotech, Long Ideas, News, Health Care, Small Cap, FDA, Movers, Trading Ideas, General
Compared to the active control irbesartan, the study met its pre-specified interim primary efficacy endpoint, demonstrating a more than threefold reduction of proteinuria from baseline after 36 weeks of treatment.
Travere Therapeutics Announces Positive Topline Interim Results from the Ongoing Phase 3 PROTECT Study of Sparsentan in IgA Nephropathy
16 Aug 21
News
Travere Therapeutics, Inc. (NASDAQ:TVTX) today announced positive topline interim results from the ongoing pivotal Phase 3 PROTECT Study of sparsentan, an investigational product candidate for the treatment of IgA
10 Health Care Stocks Showing Unusual Options Activity In Today's Session
2 Aug 21
Options
This unusual options alert can help traders discover the next big trading opportunities. Traders will search for circumstances when the market estimation of an option diverges heavily from its normal worth. Unusual trading activity could push option prices to exaggerated or underestimated levels.
Travere Therapeutics: Q2 Earnings Insights
29 Jul 21
Earnings
Shares of Travere Therapeutics (NASDAQ:TVTX) were flat in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share were down 77.27% over the past year to ($0.39), which beat the estimate of ($0.68).
Travere Therapeutics Q2 EPS $(0.39) Beats $(0.68) Estimate, Sales $54.62M Beat $50.33M Estimate
29 Jul 21
Earnings, News
Travere Therapeutics (NASDAQ:TVTX) reported quarterly losses of $(0.39) per share which beat the analyst consensus estimate of $(0.68) by 42.65 percent. This is a 77.27 percent decrease over losses of $(0.22) per share
The Daily Biotech Pulse: Merck's Disappointing Q2, Atreca Falls On Data, FDA Nod For Viatris, Nuvalent, Icosavax IPOs
29 Jul 21
Biotech, Earnings, News, Penny Stocks, Guidance, Small Cap, FDA, IPOs, General
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 28)

Press releases

Pro users get this 30m faster
Travere Therapeutics to Report Third Quarter 2021 Financial Results
14 Oct 21
News, Press Releases
SAN DIEGO, Oct. 14, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ:TVTX) today announced it will report third quarter 2021 financial results on Thursday, October 28, 2021 after the close of the U.S.
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
13 Oct 21
Markets, Press Releases
SAN DIEGO, Oct. 13, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ:TVTX) today announced that on October 10, 2021, the Compensation Committee of its Board of Directors granted inducement equity grants
Travere Therapeutics Announces Transition of Chief Medical Officer
12 Oct 21
News, Management, Press Releases
SAN DIEGO, Oct. 12, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ:TVTX) today announced that its chief medical officer, Noah Rosenberg, M.D., has chosen to transition for personal reasons to an executive
Vifor Pharma and Travere Therapeutics announce licensing agreement for the commercialization of sparsentan in Europe, Australia and New Zealand
16 Sep 21
Press Releases
Sparsentan is a potential first-in-class treatment to address significant unmet medical need in rare kidney disorders focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN) Vifor Pharma obtains
Travere Therapeutics and Vifor Pharma Announce Licensing Agreement for the Commercialization of Sparsentan in Europe, Australia and New Zealand
15 Sep 21
Press Releases
Vifor Pharma obtains exclusive commercialization rights for sparsentan in Europe, Australia and New Zealand Travere receives a $55 million upfront payment and is eligible for additional regulatory and commercial
Travere Therapeutics Appoints Ruth Williams-Brinkley to its Board of Directors
14 Sep 21
News, Management, Press Releases
SAN DIEGO, Sept. 14, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ:TVTX) today announced the appointment of Ruth Williams-Brinkley to the Company's Board of Directors, effective immediately. Ms.
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
13 Sep 21
Health Care, Markets, Press Releases
SAN DIEGO, Sept. 13, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ:TVTX) today announced that on September 10, 2021, the Compensation Committee of its Board of Directors granted inducement equity grants
Ligand Partner Travere Therapeutics Announces Positive Topline Interim Results from the Ongoing Phase 3 PROTECT Study of Sparsentan in IgA Nephropathy
16 Aug 21
Press Releases
Sparsentan treatment demonstrated a statistically significant mean reduction of proteinuria from baseline after 36 weeks, more than threefold the reduction of active comparator irbesartan (p<0.0001) Sparsentan has
Thinking about buying stock in Travere Therapeutics, ADMA Biologics, Surgalign, CTI BioPharma, or OpGen?
16 Aug 21
Opinion, Press Releases
NEW YORK, Aug. 16, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for TVTX, ADMA, SRGA, CTIC, and OPGN.
Travere Therapeutics Reports Second Quarter 2021 Financial Results
29 Jul 21
Earnings, Press Releases
Company expects to submit an application for conditional marketing authorization of sparsentan for FSGS in Europe before year-end 2021 Pivotal PROTECT Study of sparsentan in IgA nephropathy on track to report topline
Travere Therapeutics to Report Second Quarter 2021 Financial Results
22 Jul 21
News, Press Releases
SAN DIEGO, July 22, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ:TVTX) today announced it will report second quarter 2021 financial results on Thursday, July 29, 2021 after the close of the U.S.